Preimplantaion Genetic Diagnosis using Microarrays/NGS for Blastomere/Trophectoderm/Polar Body (pilot) (in Collaboration with UK NEQAS Clinical Cytogenetics)|
Extension of scope pending.
Prenatal Genetic Diagnosis testing of Polar Bodies using array/NGS technology.
PURPOSE OF PROGRAMME:
To establish the cytogenomic analytical and interpretative capabilities of the participating laboratory.
MATERIAL PROVIDED: DNA
DISTRIBUTIONS PER YEAR: 1
SAMPLES PER DISTRIBUTION: 2
FREQUENCY OF DISTRIBUTION: 1 distribution in accordance with the annual EQA timetable, offered in collaboration with UK NEQAS for Molecular Genetics
PROGRAMME OF ANALYSIS:
Two cases consisting of two Polar Body DNA samples (PB1 and PB2) each are sent to the laboratory, each with a referral card to mimic a routine diagnostic case. Instructions and a user guide are available on the website. The participant analyses the sample, interprets the results and reports via the CEQAS website. The EQA is open for 5 weeks. Results can be entered at any time during this period. Any non-submitting labs will be contacted and given 24 hours to submit a late result.
All EQA cases are validated prior to release. Results are assessed by a panel of experts against set marking criteria based upon professional guidelines. There are three marking categories, Analytical, Interpretation and Clerical Accuracy. Each category carries two points. Deductions are made in accordance with the severity of the omission. A “critical error” is an error made in either the analytical or interpretive category that could lead to serious clinical consequences or imply a significa
Satisfactory/Poor. A non-submission is also given a poor performance.
PERSISTENT POOR PERFORMANCE:
This is defined as: a) Two poor performances in any PGD Polar Body Array/NGS EQA in which the laboratory participates, over three or more distributions of material, within a 36 month rolling period; b) A poor performance within one year following a previous persistent poor performance designation.
The External Quality Assessment Scheme for Molecular Genetics was founded in 1991. In 1999 the Service became known as the UK National External Quality Assessment Service for Molecular Genetics. UK NEQAS for Molecular Genetics is part of NHS Lothian.